Background: Comparative data on the cardiac impact of different antiretro-viral therapy (ART) regimens in sub-Saharan Africa remain limited. The aim of this study was to determine which ART regimen is most associated with cardiac abnormalities during follow-up of patients at the University Clinics of Kinshasa. Methods: A historical cohort study was conducted at the University Clinics of Kinshasa among adult patients living with HIV who had been receiving ART for at least six months. Clinical, biological, and echocardiographic data were collected from medical records, standardized interviews, and clinical examinations. Patients were compared according to the ART regimen received: TDF 3TC EFV or TDF 3TC LPV/r. Statistical analyses were performed using SPSS version 25, with a significance threshold set at p < 0.05. Results: A total of 154 patients were included, with a mean age of 50.6 ± 12 years; 52.6% were male. No significant differences were observed between groups regarding age, sex, body mass index (BMI), blood pressure, CD4 count (204.5 cells/mm3), or median viral load (510 copies/mL). Patients receiving LPV/r more frequently presented with asthenia (17.6% vs 3.6%, p = 0.041), tachycardia (29.4% vs 14.6%, p = 0.011), higher white blood cell counts (p = 0.028), and significantly elevated C-reactive protein levels (77.8 vs 40.0 mg/dL, p = 0.014). Blood urea levels were also higher in this group (p = 0.018). Dilated cardiomyopathy was observed only in patients receiving EFV (16.8%, p = 0.016), whereas segmental wall motion abnormalities were more frequent in patients treated with LPV/r (17.6%, p = 0.030). Conclusion: Cardiac abnormalities and inflammation are common among people living with HIV receiving ART, with distinct profiles depending on the therapeutic regimen. These findings highlight the need for systematic and individualized cardiovascular monitoring in this population.
Cite this paper
Lupenzi, B. M. , Nkodila, A. N. , Kintoki, E. V. , Kasiam, J. B. and Longo-Mbenza, B. (2026). Cardiac Abnormalities among Patients Receiving Antiretroviral Therapy at the University Clinics of Kinshasa, Democratic Republic of the Congo. Open Access Library Journal, 13, e15015. doi: http://dx.doi.org/10.4236/oalib.1115015.
Trickey, A., May, M.T., Vehreschild, J., Obel, N., Gill, M.J., Crane, H.M., et al. (2017) Survival of HIV-Positive Patients Starting Antiretroviral Therapy between 1996 and 2013: A Collaborative Analysis of Cohort Studies. The Lancet HIV, 4, e349-e356. https://doi.org/10.1016/s2352-3018(17)30066-8
Ogyefo, I.N., Obese, V., Norman, B.R., Owusu, I.K., Nkum, B. and Kokuro, C. (2024) Prevalence and Patterns of Echocardiographic Abnormalities among People Living with HIV on Anti-Retroviral Therapy in Kumasi, Ghana. BMC Cardiovascular Disorders, 24, Article No. 453. https://doi.org/10.1186/s12872-024-04117-1
Bloomfield, G.S., Khaza-nie, P., Morris, A., Rabadán-Diehl, C., Benjamin, L.A., Murdoch, D., et al. (2014) HIV and Noncommunicable Cardiovascular and Pulmonary Diseases in Low- and Middle-Income Countries in the ART Era: What We Know and Best Directions for Future Research. JAIDS Journal of Acquired Immune Deficiency Syndromes, 67, S40-S53. https://doi.org/10.1097/qai.0000000000000257
Casper, C., Crane, H., Menon, M. and Money, D. (2017) HIV/AIDS Comorbidities: Impact on Cancer, Noncommunicable Diseases, and Reproductive Health. In: Holmes, K., Bertozzi, S., Bloom, B. and Jha, P., Eds., Disease Control Priorities, Third Edi-tion (Volume 6): Major Infectious Diseases, The World Bank, 45-66. https://doi.org/10.1596/978-1-4648-0524-0_ch3
Sliwa, K., Carrington, M.J., Becker, A., Thienemann, F., Ntsekhe, M. and Stewart, S. (2012) Contribu-tion of the Human Immunodeficiency Virus/Acquired Immunodeficiency Syn-drome Epidemic to De Novo Presentations of Heart Disease in the Heart of So-weto Study Cohort. European Heart Journal, 33, 866-874. https://doi.org/10.1093/eurheartj/ehr398
Ntusi, N.A., Badri, M. and Gumedze, F. (2010) Echocardiographic Abnormalities in HIV-Infected Patients Receiving Antiretroviral Therapy in Cape Town, South Africa. Heart, 96, 1767-1772.
Traoré, A., Dakoua, R., Sogodo, A., Camara, Y., Sidibé, N., Menta, I., et al. (2023) Prévalence et aspects cliniques des affections cardiovasculaires chez les personnes vivant avec le VIH/SIDA en cours de traitement au CHU Gabriel Touré. Health Sciences and Disease, 24, No. 7.
Longo-Mbenza, B., Seghers, K.V., Phuati, M., Nkiabungu Bikangi, F. and Mubagwa, K. (1998) Heart Involvement and HIV Infection in African Patients: Determinants of Survival. International Journal of Cardiology, 64, 63-73. https://doi.org/10.1016/s0167-5273(97)00321-5
Menanga, A.P., Ngomseu, C.K., Jingi, A.M., Mfangam, B.M., Noubiap, J.J., Gweth, M.N., Blackett, K.N. and Kingue, S. (2015) Patterns of Cardiovascular Disease in a Group of HIV-Infected Adults in Yaoundé, Cameroon. Cardiovascular Diagnosis and Therapy, 5, 420-427.
Smit, M., Brinkman, K., Geerlings, S., Smit, C., Thyagarajan, K., van Sighem, A., et al. (2021) Future Challenges for Clinical Care of an Ageing Population Infected with HIV. The Lancet Infectious Diseases, 21, e83-e96.
Nagueh, S.F., Smiseth, O.A., Appleton, C.P., Byrd, B.F., Dokainish, H., Edvardsen, T., et al. (2016) Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardi-ovascular Imaging. Journal of the American Society of Echocardiography, 29, 277-314. https://doi.org/10.1016/j.echo.2016.01.011
Phillips, A.N., Lundgren, J.D. and Sabin, C.A. (2020) Risk of Cardiovascular Disease in HIV Patients Receiving Protease Inhib-itors. HIV Medicine, 21, 211-220.
Gili, S., Russo, G. and Sciarrone, M.T. (2022) Antiretroviral Therapy and Car-dio-Vascular Symptoms: Focus on Efavirenz. Current HIV Research, 20, 45-54.
World Health Organization (2021) Consolidated Guidelines on HIV, Viral Hepatitis and STI Prevention, Diagnosis, Treatment and Care. World Health Organization. https://www.who.int
Feinstein, M.J., Hsue, P.Y., Benjamin, L.A., et al. (2020) Characteristics, Prevention, and Management of Cardiovascular Disease in People Living with HIV. Circulation, 141, e98-e124.
Reiss, P., Rakhmanina, N. and Mallon, P.W.G. (2023) Cardiovascular Risk and Antiretro-viral Therapy: Where Are We Now? Current Opinion in HIV and AIDS, 18, 87-95.
Hsu, D.C., Ma, Y.F., Hur, S., et al. (2021) Plasma IL-6 and CRP Lev-els Are Associated with Cardiovascular Events in Treated HIV Infection. AIDS, 35, 263-273.
Serrano-Villar, S., Martínez-Sanz, J. and Moreno, S. (2020) Immune Activation and Cardiovascular Disease in HIV. Current Opinion in In-fectious Diseases, 33, 20-26.
Bloomfield, G.S., Leung, C. and Hsue, P.Y. (2022) Cardiovascular Disease in People Living with HIV: Evolving Knowledge and Future Directions. Journal of the American College of Cardiology, 80, 299-314.
Freiberg, M.S., Chang, C.C.H., Skanderson, M., et al. (2023) Inflammation, Immune Activation, and Cardiovascular Disease in HIV. The Lan-cet HIV, 10, e252-e263.
Lakatta, E.G. and Levy, D. (2003) Arterial and Cardiac Aging: Major Shareholders in Cardiovascular Disease Enterprises. Cir-culation, 107, 139-146. https://doi.org/10.1161/01.cir.0000048892.83521.58
Freiberg, M.S., Chang, C.H., Kuller, L.H., Skanderson, M., Lowy, E., Kraemer, K.L., et al. (2013) HIV Infection and the Risk of Acute Myocardial Infarction. JAMA Internal Medicine, 173, 614-622. https://doi.org/10.1001/jamainternmed.2013.3728
Friis-Møller, N., Reiss, P., Sabin, C.A., et al. (2007) Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. New England Journal of Medicine, 356, 1723-1735.
Triant, V.A., Lee, H., Hadigan, C. and Grinspoon, S.K. (2010) Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with HIV Disease. Journal of Clinical Endocrinology & Metabo-lism, 95, 17-23.
